Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment.
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
02
06
2020
revised:
20
07
2020
accepted:
27
07
2020
pubmed:
29
8
2020
medline:
20
5
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Brain metastases (BM) frequently cause focal neurological deficits leading to a reduced Karnofsky performance score (KPS). Since KPS is routinely used to guide the choice of adjuvant therapy, we hypothesized that improving KPS by surgical resection may improve the chance for adjuvant treatment and ultimately result in better survival. We therefore analyzed the course of a large cohort undergoing resection of symptomatic brain metastases in the context of further treatment and clinical outcome. In a bi-centric retrospective analysis we retrieved baseline, clinical, and treatment-related parameters of patients operated on BM between 2010 and 2019. Survival was calculated using Kaplan-Meier estimates; prognostic factors for survival were analyzed by Log-rank test and Cox proportional hazards. We included 750 patients with a median age of 61 (19-87) years. The functional status was significantly improved by surgical resection, with a median preoperative (KPS) of 80 (10-100) increasing to 90 (0-100) after surgery (P < .0001). Moreover, surgery improved the RTOG recursive partitioning analysis (RPA) class from III to I/II in 82 patients. Postoperative local radiotherapy and systemic treatment were associated with significantly longer survival (P < .0001 for each). Systemic treatment was provided significantly more frequently in patients with a fair postoperative clinical status (KPS ≥ 70; P < .0001). The postoperative clinical status, postoperative radiotherapy, systemic treatment, controlled systemic disease and < 4 BM were independent predictors for survival. The resection of symptomatic BM may restore clinical status, so enhancing the likelihood of receiving adjuvant treatment, and therefore leading to improved overall survival.
Sections du résumé
BACKGROUND
Brain metastases (BM) frequently cause focal neurological deficits leading to a reduced Karnofsky performance score (KPS). Since KPS is routinely used to guide the choice of adjuvant therapy, we hypothesized that improving KPS by surgical resection may improve the chance for adjuvant treatment and ultimately result in better survival. We therefore analyzed the course of a large cohort undergoing resection of symptomatic brain metastases in the context of further treatment and clinical outcome.
PATIENTS AND METHODS
In a bi-centric retrospective analysis we retrieved baseline, clinical, and treatment-related parameters of patients operated on BM between 2010 and 2019. Survival was calculated using Kaplan-Meier estimates; prognostic factors for survival were analyzed by Log-rank test and Cox proportional hazards.
RESULTS
We included 750 patients with a median age of 61 (19-87) years. The functional status was significantly improved by surgical resection, with a median preoperative (KPS) of 80 (10-100) increasing to 90 (0-100) after surgery (P < .0001). Moreover, surgery improved the RTOG recursive partitioning analysis (RPA) class from III to I/II in 82 patients. Postoperative local radiotherapy and systemic treatment were associated with significantly longer survival (P < .0001 for each). Systemic treatment was provided significantly more frequently in patients with a fair postoperative clinical status (KPS ≥ 70; P < .0001). The postoperative clinical status, postoperative radiotherapy, systemic treatment, controlled systemic disease and < 4 BM were independent predictors for survival.
CONCLUSION
The resection of symptomatic BM may restore clinical status, so enhancing the likelihood of receiving adjuvant treatment, and therefore leading to improved overall survival.
Identifiants
pubmed: 32858763
doi: 10.1002/cam4.3402
pmc: PMC7571801
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7503-7510Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
JAMA Oncol. 2017 Jun 1;3(6):827-831
pubmed: 27892978
Clin Cancer Res. 2019 Nov 15;25(22):6570-6580
pubmed: 31213459
Cancer Discov. 2015 Nov;5(11):1164-1177
pubmed: 26410082
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
pubmed: 9128946
J Clin Oncol. 2015 Oct 20;33(30):3475-84
pubmed: 26282648
Neurosurgery. 2005 May;56(5):1021-34; discussion 1021-34
pubmed: 15854250
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e59-e69
pubmed: 31099629
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):655-61
pubmed: 19942357
Acta Neurochir (Wien). 2013 Mar;155(3):389-97
pubmed: 23325516
N Engl J Med. 1990 Feb 22;322(8):494-500
pubmed: 2405271
Anticancer Res. 2017 Sep;37(9):4859-4865
pubmed: 28870906
Acta Neurochir (Wien). 2013 Mar;155(3):379-87
pubmed: 23314988
J Clin Neurosci. 2020 Mar;73:144-149
pubmed: 31956087
Front Oncol. 2018 Oct 09;8:415
pubmed: 30356657
Int J Mol Sci. 2013 Apr 24;14(5):8708-18
pubmed: 23615466
Lancet Oncol. 2014 Apr;15(4):387-95
pubmed: 24621620
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Nat Rev Cancer. 2020 Jan;20(1):26-41
pubmed: 31601988
Ecancermedicalscience. 2013 Apr 18;7:308
pubmed: 23634178
World Neurosurg. 2017 Jan;97:169-177
pubmed: 27667577
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1001-6
pubmed: 10863071
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Arch Neurol. 1978 Nov;35(11):754-6
pubmed: 718475
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Cancer Med. 2020 Oct;9(20):7503-7510
pubmed: 32858763
Neurosurgery. 2019 Mar 1;84(3):550-552
pubmed: 30629218
Ann Neurol. 1993 Jun;33(6):583-90
pubmed: 8498838
BMC Med Inform Decis Mak. 2013 Jul 19;13:72
pubmed: 23870327